Mirum Pharmaceuticals, Inc. MIRM
We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. 10-K, Item 1
- Headquarters
- Foster City, CA
- CEO
- Christopher Peetz
- Next results
- around Jan 11, 2027
MIRM among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
41 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Inventory Costing (“As described in Notes 2 and 5 to the consolidated financial statements, inventory, which totaled $24.9 million as of December 31, 2025, is comprised of raw materials, work-in-progress and finished goods. Inventory is valued at the lower of cost or net realizable value, with cost determined on a firs”). No longer listed: Inventory. Same as last year: Table of Contents
-
Receivables +57.5% ($78.3M to $123.3M) vs revenue +54.7% ($336.9M to $521.3M), +2.8 pts apart
9 more checks with nothing to note
-
Cash from operations $55.8M vs net income −$23.4M (FY ending Dec 31, 2025)
-
Inventory +11.1% ($22.4M to $24.9M) vs revenue +54.7% ($336.9M to $521.3M), -43.7 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
41 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
In clinical studies of brelovitug, the most common treatment-related AEs were injection-related events that resolved within 1-2 days, and cases of flu-like illness that were mild-moderate in severity.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
We participate in, or are subject to, the Medicaid Drug Rebate Program, as administered by Centers for Medicare & Medicaid Services (“CMS”), and other federal and state government pricing programs in the U.S., and we may participate, or be asked to participate, in additional government pricing programs or supplemental rebates in the…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
If generic manufacturers are successful in their use of litigation or regulatory means to obtain approval for generic versions of LIVMARLI, our revenue and results of operations would be adversely affected. The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments of the Federal Food, Drug,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
There have also been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act (“Affordable Care Act”) was enacted in the U.S., which substantially changed the way…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $77.1M | $186.4M | $336.9M | $521.3M |
| Net income | −$135.7M | −$163.4M | −$87.9M | −$23.4M |
| Operating cash flow | −$120.1M | −$70.9M | $10.3M | $55.8M |
| Free cash flow | −$120.4M | −$71.1M | $9.3M | $54.9M |
Revenue, FY2020 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$521.3M ▲ 54.7% in FY2025−$23.4M in FY2025$54.9M ▲ 488.0% in FY2025
Recent filings
10 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026LAURA BREGE (Director) gave notice of a planned sale of 14,167 shares worth about $1.3M Form 144, approximate sale date Nov 11, 2026
-
8-KNov 10, 2026Other events 8-K item 8.01
-
Planned saleNov 4, 2026CHRISTOPHER PEETZ (Officer, Director) gave notice of a planned sale of 20,000 shares worth about $1.8M Form 144, approximate sale date Nov 4, 2026, under a 10b5-1 plan adopted Mar 2, 2026
-
Planned saleNov 4, 2026Joanne Quan (Former Officer) gave notice of a planned sale of 14,684 shares worth about $1.4M Form 144, approximate sale date Nov 4, 2026
-
Planned saleNov 3, 2026Peter Radovich (President and Chief Operating Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 106,608 shares, runs to Aug 10, 2027
About the company
Mirum Pharmaceuticals, Inc., Foster City, CA · from the 10-K filed Feb 25, 2026
We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”).
- Headquarters
- Foster City, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.